Evaluation of HCV-Core Antigen in Diagnosis of Chronic Hepatitis C Patients under Direct-Acting Antiviral Treatment

Creative Commons License

TOYGAR DENİZ M., AKHAN S., SAYAN M., Tamer G. S., AZAK KARALİ E.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, vol.28, no.1, pp.25-31, 2022 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.4274/vhd.galenos.2022.2021-3-2
  • Journal Name: VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.25-31
  • Keywords: Hepatitis C virus, correlation, viral load, hepatitis C antibodies, CLINICAL UTILITY, ENZYME-IMMUNOASSAY, ASSAY, QUANTIFICATION, EPIDEMIOLOGY, PERFORMANCE, INFECTION, BURDEN, RNA
  • Kocaeli University Affiliated: Yes

Abstract

Objectives: Recently, with the use of direct-acting antivirals (DAA) for treating chronic hepatitis C (CHC), the success rate has exceeded 90%. The implementation of these strong therapies has reduced the role of monitoring therapy with hepatitis C virus (HCV)-RNA tests. The current study compares the HCV-core antigen test (HCV-Ag) with HCV-RNA in terms of correlation, effectiveness and cost in patients who started DAA and to evaluate the usability of HCV-Ag as a routine laboratory test.